Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

NICE has decided to withdraw the final draft guidance for elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026] and instead will be issuing draft guidance to consult on the optimised recommendation. NICE will hold a 28-day consultation in which stakeholders invited to comment on the draft guidance document. NICE will then hold a committee meeting to consider the consultation responses. As there will continue to be a positive draft recommendation for managed access in the relevant population, interim funding will remain available for patients eligible for elranatamab under this recommendation.